Bildkälla: Stockfoto

Corline Q2 confirms increasing future potential - Redeye

Redeye’s points to more robust potential partner support for CHS coated medical devices. This includes both existing partner Imperative Care and Kardium plus the recently added new partner. Corline also has a handful of late-stage potential new partner leads. Corline continues to prepare ahead of the Renaparid study RENAPAIR 02, and the ambition remains to initiate a study in late 2021. We can expect a more detailed update already late in September.

Redeye’s points to more robust potential partner support for CHS coated medical devices. This includes both existing partner Imperative Care and Kardium plus the recently added new partner. Corline also has a handful of late-stage potential new partner leads. Corline continues to prepare ahead of the Renaparid study RENAPAIR 02, and the ambition remains to initiate a study in late 2021. We can expect a more detailed update already late in September.
Börsvärldens nyhetsbrev
ANNONSER